Chinese Journal of Pharmacovigilance ›› 2021, Vol. 18 ›› Issue (11): 1080-1082.
DOI: 10.19803/j.1672-8629.2021.11.18

Previous Articles     Next Articles

Safety Risks of Somatostatin for Injection

WANG Chunting1, MA Minkang2, ZHENG Mingjie1   

  1. 1Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China;
    2Zhejiang Center for ADR Monitoring, Hangzhou Zhejiang 310012, China
  • Received:2021-08-26 Published:2021-11-18

Abstract: Objectiv eTo analyze the risks of somatostatin for injection so as to provide reference for clinical rational drug use. Methods The related adverse drug reaction reports in WHO VigiAccess and China adverse drug reaction database were analyzed. The cases of adverse drug reactions caused by somatostatin for injection reported in China were summarized. Instructions for somatostatin for injection and risk control measures and were statistically analyzed. Results Adverse drug reactions of somatostatin for injection involved multiple systems or organs, including gastrointestinal system damage, skin and accessory damage, cardiovascular system damage, metabolic and nutritional disorders. The main serious adverse drug reactions were allergic reactions, which could lead to allergic shock. Conclusion The serious allergic reactions induced by somatostatin for injection deserve more attention. Drug instructions should be made more specific while clinical safe and rational drug use should be ensured.

Key words: somatostatin for injection, adverse drug reactions, allergic shock, safety, risk

CLC Number: